Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Key

The oncologist

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

19-11-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

13-11-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

The New England journal of medicine

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

07-11-2024

European journal of cancer (Oxford, England : 1990)

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

01-11-2024

Nature medicine

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

01-11-2024

International journal of cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

15-10-2024

ESMO open

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

01-10-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

01-10-2024

The New England journal of medicine

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

15-09-2024

Frontiers in immunology

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

11-09-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.

02-09-2024

Oncoimmunology

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

27-08-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Clinical nuclear medicine

Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.

01-08-2024

JAMA network open

Long-Term Survival in Patients With Advanced Melanoma.

01-08-2024

Cancers

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

26-07-2024

Cancer discovery

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.

01-07-2024

Journal for immunotherapy of cancer

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

30-06-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.

01-06-2024

Cancer medicine

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

01-06-2024

Scientific reports

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

16-05-2024

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024

Cancer

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

01-05-2024

Nature biotechnology

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

23-04-2024

Med (New York, N.Y.)

Melanoma neoantigen vaccines: Are we getting more personal now?

12-04-2024

Oncology research and treatment

Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial.

08-04-2024

The Lancet regional health. Europe

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.

01-04-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.

01-04-2024

Journal for immunotherapy of cancer

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

26-03-2024

Cancer journal (Sudbury, Mass.)

Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma.

25-03-2024

Nature reviews. Clinical oncology

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

01-03-2024

EClinicalMedicine

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

01-03-2024

Cancer discovery

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.

01-03-2024

Journal for immunotherapy of cancer

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.

29-02-2024

Nature communications

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

23-02-2024

ESMO open

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.

01-02-2024

Clinical nuclear medicine

The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

01-02-2024

Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024

Journal for immunotherapy of cancer

No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC.

31-01-2024

Pigment cell & melanoma research

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

01-01-2024

Immuno-oncology technology

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.

01-12-2023

The New England journal of medicine

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

09-11-2023

Nature medicine

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

01-11-2023

Cancer discovery

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

05-10-2023